Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
CyBorD regimen
Introduction
Synonyms and keywords:Bortezomib/Cyclophosphamide/Dexamethasone Regimen; CyBorD; VCD; Velcade-Cyclophosphamide-Dexamethasone
Overview
Overview
CyBorD regimen refers to a treatment regimen consisting of a combination of cyclophosphamide, bortezomib (Velcade) and dexamethasone three-drug induction regimen for untreated transplant-eligible multiple myeloma patients[1] and AL amyloidosis[2]
Regimen
Regimen
CyCyclophosphamide
BorBortezomib (Velcade)
DDexamethasone
References
References
- ↑ 1.0 1.1 Areethamsirikul N, Masih-Khan E, Chu CM, Jimenez-Zepeda V, Reece DE, Trudel S; et al. (2015). “CyBorD induction therapy in clinical practice”. Bone Marrow Transplant. 50 (3): 375–9. doi:10.1038/bmt.2014.288. PMID 25599165.
- ↑ 2.0 2.1 Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB; et al. (2012). “Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis”. Blood. 119 (19): 4391–4. doi:10.1182/blood-2011-11-390930. PMC 3557400. PMID 22331188.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]